No­vo Nordisk to re­strict starter dose sup­ply for weight loss drug We­govy

Faced with “all-time high lev­els” of new pa­tients start­ing No­vo Nordisk’s GLP-1 prod­ucts, the com­pa­ny is tem­porar­i­ly re­strict­ing its sup­ply of low­er We­govy dose strengths …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER